Agilent Technologies has launched Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organisation (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States (US).

Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customisable manufacturing solutions.

Agilent Advanced Therapeutics’ CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs and cell line development. The integrated platform provides customers streamlined access to end-to-end development and manufacturing services through a single partner — from discovery and process development through clinical- and commercial-scale manufacturing.

“The Agilent Advanced Therapeutics solution strengthens our ability to support our customers and reinforces our long-term commitment to growth, investment and leadership in this space. For our customers, this means a more integrated experience, deeper technical partnership and a trusted team that understands what it takes to bring life-changing therapies to patients,” said Padraig McDonnell, CEO and President, Agilent.

The company generated revenue of USD 6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.

Simon May, President, Life Sciences and Diagnostics Markets Group, Agilent, added, “This launch reflects the combined excellence of our teams and our commitment to advancing the next generation of therapies. We are excited to bring our unified Agilent Advanced Therapeutics capabilities to partners around the world.”